Abstract:

Tuberculosis is a communicable disease caused by Mycobacterium tuberculosis, considered a major risk to global health security. This study determined the prevalence, treatment outcomes, and factors associated with tuberculosis among 737 presumptive tuberculosis patients in Federal Capital Territory Abuja, Nigeria from 1^st April 2019 to 30^th May 2021 through retrospective cross-sectional study and multi-stage sampling. From Non-Municipal Area Councils, Bwari was selected while from Health Facilities, General Hospital Bwari and Gwarimpa were selected from Bwari and Abuja Municipal Area Council respectively by simple random sampling and data abstractions were done and analyzed using Statistical Package for Social Sciences version 23.0 Software. The prevalence of tuberculosis amongst the patients was 19.4%. The tuberculosis treatment outcome showed that 66.4% were cured, 14.7% completed treatment, 7.0% failed treatment, 5.6% lost to follow-up and 0.7% removed from the Register. The prevalence of tuberculosis in the Bwari Area Council was 8.2%. The association between Area Council of Resident and tuberculosis was significant (p = 0.001). Patients that reside in Bwari Area Council were 0.078 times less likely to have tuberculosis compared to those who reside in Abuja Municipal Area Council and, Area Council of Residence was a predictor of tuberculosis (aOR = 0.001; 95% C.I. = 0.043 - 0.141). The prevalence of tuberculosis amongst patients with Human Immunodeficiency Virus was 29.6%. The association was significant (p = 0.001) but not a predictor of tuberculosis (aOR = 0.840; 95% C.I. = 0.617 - 1.810).

References:

[1] Tiewsoh, J. A., Antony, B., & Boloor, R. (2020). HIV-TB co-infection with clinical presentation, diagnosis, treatment, outcome, and its relation to CD4 count, a cross-sectional study in a tertiary care hospital in coastal Karnataka. Journal of Family Medicine and Primary Care, 9(2), 1160. https://doi.org/10.4103/jfmpc.jfmpc_950_19.

[2] KNCV Tuberculosis Foundation. (n.d.). What is tuberculosis? - KNCV - Tuberculosefonds. Retrieved March 30, 2021, from https://www.kncvtbc.org/en/about-tb/.

[3] World Health Organization. (2020). Global tuberculosis report 2020: executive summary. https://apps.who.int/iris/bitstream/handle/10665/337538/9789240016095-eng.pdf.

[4] ALNAP. (2020). Global Tuberculosis Report 2020 | ALNAP. Retrieved April 10, 2021, from https://www.alnap.org/help-library/global-tuberculosis-report-2020.

[5] World Health Organization. (2020). Global Tuberculosis Report 2020 | HIV/AIDS Data Hub for the Asia-Pacific Region. Retrieved April 10, 2021, from https://www.aidsdatahub.org/resource/global-tuberculosis-report-2020.

[6] Floyd, K., Glaziou, P., Zumla, A., & Raviglione, M. (2018). The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era. The Lancet Respiratory Medicine, 6(4), 299–314. https://doi.org/10.1016/S2213-2600(18)30057-2.

[7] USAID. (2009). Standard Operating Procedures for Implementation of TB Activities at HIV/AIDS Service Delivery Sites Collaborative TB/HIV Services. Retrieved April 17, 2021, from https://challengetb.org/publications/tools/tb_hiv/SOPCollaborativeTBHIVServices.pdf.

[8] World Health Organization. (2020). Tuberculosis. Retrieved March 30, 2021, from https://www.who.int/news-room/fact-sheets/detail/tuberculosis.

[9] Centers for Disease Control and Prevention. (2016). Basic TB Facts | TB | CDC. Retrieved March 30, 2021, from https://www.cdc.gov/tb/topic/basics/default.htm.

[10] National Health System. (2019). Tuberculosis (TB) - Causes - NHS. https://www.nhs.uk/conditions/tuberculosis-tb/causes/.

[11] The Global Fund. (2021). Tuberculosis - The Global Fund to Fight AIDS, Tuberculosis and Malaria. Retrieved April 10, 2021, from https://www.theglobalfund.org/en/tuberculosis/.

[12] World Health Organization. (2018). HIV/AIDS | WHO | Regional Office for Africa. Retrieved April 11, 2021, from https://www.afro.who.int/health-topics/hivaids.

[13] Measure evaluation. (n.d.). Frameworks Module 250706.ppt — Measure Evaluation. Retrieved March 31, 2021, from https://www.measureevaluation.org/resources/training/capacity-building-resources/phn/course-modules/week-1/Frameworks Module 250706.ppt/view.

[14] Federal Ministry of Health Nigeria. (2010). National Tuberculosis and Leprosy Control Programme: Workers’ manual – Revise 5th Edition 1. Retrieved April 2, 2021, from https://www.who.int/hiv/pub/guidelines/nigeria_tb.pdf.

[15] Adebisi, Y. A., Agumage, I., Sylvanus, T. D., Nawaila, I. J., Ekwere, W. A., Nasiru, M., Okon, E. E., Ekpenyong, A. M., & Lucero-Prisno III, D. E. (2019). Burden of Tuberculosis and Challenges Facing Its Eradication in West Africa. International Journal of Infection, 6(3). https://doi.org/10.5812/iji.92250.

[16] Ologunde, C. A., Anidiobu, C. O., Oluwasusi, V. O., & Ilesanmi, T. M. (2021). Prevalence of Tuberculosis and Human Immunodeficiency Virus (HIV) in Ikere-Ekiti, Ekiti State Southwestern Nigeria. South Asian Journal of Research in Microbiology, 9(1), 1–5. https://doi.org/10.9734/sajrm/2021/v9i130198.

[17] Hassan, A., Olukolade, R., Ogbuji, Q., Onyemocho, A., Okwuonye, L., Igbabul, S., Okechukwu, J., Kusimo, O., Osho, A., Osinowo, K., & Ladipo, O. (2016). Evaluation of Tuberculosis Treatment Outcome of TB/HIV Co-Infection: A Four-Year Retrospective Cohort Study in HIV-Prevalent Setting of North Central Nigeria. Journal of Tuberculosis Research, 04(03), 122–133. https://doi.org/10.4236/jtr.2016.43015.

[18] Dye, C., Harries, A. D., Maher, D., Hosseini, S. M., Nkhoma, W., & Salaniponi, F. M. (2006). Tuberculosis. In Disease and Mortality in Sub-Saharan Africa. The International Bank for Reconstruction and Development / The World Bank. http://www.ncbi.nlm.nih.gov/pubmed/21290646.

[19] Centers for Disease Control and Prevention. (2020). Global Health - Newsroom - Tuberculosis. Retrieved April 10, 2021, from https://www.cdc.gov/globalhealth/newsroom/topics/tb/index.html.

[20] Nwokoro, U. U., Dahiru, T., Olorukooba, A., Daam, C. K., Waziri, H. S., Adebowale, A., Waziri, N. E., & Nguku, P. (2020). Determinants of perinatal mortality in public secondary health facilities, Abuja municipal area council, Federal Capital Territory, Abuja, Nigeria. Pan African Medical Journal, 37(114), 1–12. https://doi.org/10.11604/pamj.2020.37.114.17108.

[21] Hamisu, A. W., Etapelong, S. G., Ayodeji, I. H., Furera, Z., Ningi, N., Jimoh, A., Fiona, B., Banda, R., Tegegne, S. G., Ajogwu, A., Nwachukwu, J., John, D., Abdurrahman, S., Ahmed, F., Adesola, L., Teresa, N., Adesola, O., Rahmat, A., Elizabeth, A., & Lydia, T. (2020). Assessment of the contribution of community active surveillance to covid-19 case detection in the Federal Capital Territory, Abuja, Nigeria. African Journal of Biology and Medical Research, 3(2), 98–110. www.abjournals.org.

[22] Ifeadike, C., Ironkwe, O., Nnebue, C., Nwabueze, S., Ubajaka, C., Adogu, P. O. U., & Emelumadu, O. (2012). Prevalence and pattern of bacteria and intestinal parasites among food handlers in the Federal Capital Territory of Nigeria. Nigerian Medical Journal, 53(3), 166. https://doi.org/10.4103/0300-1652.104389.

[23] Kamweli, M., Id, A., Kwaga, J., Okolocha, E., & Mba, N. (2019). Prevalence and risk factors for multi-drug resistant Escherichia coli among poultry workers in the Federal Capital Territory, Abuja , Nigeria Prevalence and risk factors for multi-drug resistant Escherichia coli among poultry workers in the Federal Capit. November. https://doi.org/10.1371/journal.pone.0225379.

[24] National Tuberculosis and Leprosy Control Programme. (2019). 2019 Annual TB Report. https://www.health.gov.ng/doc/Draft-2019-NTBLCP-Annual-report-22032020.pdf.

[25] Dememew, Z. G., Jerene, D., Datiko, D. G., Hiruy, N., Tadesse, A., Moile, T., Bekele, D., Yismawu, G., Melkieneh, K., Reshu, B., & Suarez, P. G. (2020). The yield of community-based tuberculosis and HIV among key populations in hotspot settings of Ethiopia: A cross-sectional implementation study. PLoS ONE, 15(5), e0233730. https://doi.org/10.1371/journal.pone.023373.

[26] Ejeh, F. E., Undiandeye, A., Okon, K., Kazeem, H. M., & Kudi, A. C. (2020). Isolation and Immunological Detection of Mycobacterium Tuberculosis from HIV and Non-HIV Patients in Benue State, Nigeria. Ethiopian Journal of Health Sciences, 30(1), 55–64. https://doi.org/10.4314/ejhs.v30i1.8.

[27] Inyinbor, H. E., Omosigho, P. O., Akobi, O. A., Gideon, Emumwen, E., Ogedengbe, S. O., Shehu, Kudu Mohammed, Abdullahi1, M. N., Aliyu2, N. J., Oshinsanya1, T. T., Favour, A., Emumwen4, E., & . (2020). Prevalence of Pulmonary Tuberculosis in Bida, North Central Nigeria: A fiveYear Retrospective Study. J Med Lab Sci, 30(4), 26–34.

[28] Ajide, B., Chuku, A., Lawson, L., Orole, K., & and Adogo, L. (2020). Prevalence of Mycobacterium tuberculosis in North Central Nigeria. Nigerian Journal of Microbiology, 34(2), 5325–5332. http://www.nsmjournal.org.ng/2020-34-2/12.pdf.

[29] Ekeke, N., Aniwada, E., Chukwu, J., Nwafor, C., Meka, A., Alphonsus, C., Ezeakile, O., Ajayi, A., Soyinka, F., Bakpa, F., Uwanuruochi, V., Aniekwensi, E., & Eze, C. (2020). Screening diabetes mellitus patients for tuberculosis in southern nigeria: A pilot study. Advances in Respiratory Medicine, 88(1), 6–12. https://doi.org/10.5603/ARM.2020.0072.

[30] Gebretsadik, D., Ahmed, N., Kebede, E., Mohammed, M., & Belete, M. A. (2020). Prevalence of Tuberculosis by Automated GeneXpert Rifampicin Assay and Associated Risk Factors Among Presumptive Pulmonary Tuberculosis Patients at Ataye District Hospital, Northeast Ethiopia. Infection and Drug Resistance, 13, 1507–1516. https://doi.org/10.2147/IDR.S248059.

[31] Ugwu, K. O., Agbo, M. C., & Ezeonu, I. M. (2021). Prevalence of tuberculosis, drug-resistant tuberculosis and HIV/TB co-infection in Enugu, Nigeria. African Journal of Infectious Diseases, 15(2), 24–30. https://doi.org/10.21010/ajid.v15i2.5.

[32] Tola, A., Minshore, K. M., Ayele, Y., & Mekuria, A. N. (2019). Tuberculosis Treatment Outcomes and Associated Factors among TB Patients Attending Public Hospitals in Harar Town, Eastern Ethiopia: A Five-Year Retrospective Study. Tuberculosis Research and Treatment, 2019, 1–11. https://doi.org/10.1155/2019/1503219.

[33] Teferi, M. Y., Didana, L. D., Hailu, T., Woldesenbet, S. G., Bekele, S., & Mihret, A. (2021). Tuberculosis treatment outcome and associated factors among tuberculosis patients at Wolayta Sodo Teaching and Referral Hospital, Southern Ethiopia: a retrospective study. Journal of Public Health Research, 10(3). https://doi.org/10.4081/JPHR.2021.2046.

[34] Tanue, E. A., Nsagha, D. S., Njamen, T. N., & Clement Assob, N. J. (2019). Tuberculosis treatment outcome and its associated factors among people living with HIV and AIDS in Fako Division of Cameroon. PLOS ONE, 14(7), e0218800. https://doi.org/10.1371/JOURNAL.PONE.0218800.

[35] Narasimhan, P., Wood, J., Macintyre, C. R., & Mathai, D. (2013). Risk Factors for Tuberculosis. 2013, 11. https://doi.org/10.1155/2013/828939.

[36] Abdulkader, M., Van Aken, I., Niguse, S., Hailekiros, H., & Spigt, M. (2019). Treatment outcomes and their trend among tuberculosis patients treated at peripheral health settings of Northern
Ethiopia between 2009 and 2014: A registry-based retrospective analysis. BMC Research Notes, 12(1), 1–5. https://doi.org/10.1186/S13104-019-4824-9/FIGURES/1.

[37] Mamo, A., Mama, M., Solomon, D., & Mohammed, M. (2021).

Treatment Outcomes and Predictors Among Tuberculosis Patients at Madda Walabu University Goba Referral Hospital, Southeast Ethiopia